Member Info for EmeraldCarrots

"Angle hails publication of research data in science journal"

And Astrazeneca) multi BILLION $ Companies who STILL (astonishingly) have seemingly not spent one cent investigating the potential of using circulating tumour cells (CTC'S) to measure a cancer drugs performance during a cancer drug trial. They must know how they expect their drug to work. So, they must know what to measure/monitor in the CTC's as the treatment progresses. Astrazeneca are paying Angle to develop an assay to do just that for prostate cancer.

From the RNS of 3rd May 2024:-

"ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce that it has signed a supplier agreement to develop a Parsortix-based Androgen Receptor1 (AR) detection assay for use in prostate cancer studies.".

It is totally out of order that other massive plc's are seemingly not willing to pay for an assay for their cancer drug trials that should give them information on how the CTC's are affected by their drug during the trial. This should give them a “running commentary” on the drugs affect during the trial.

Mr Newland has said he is talking to, I think he said 9 other Plc's. How long do they need to make their minds up............. A FEW YEARS!

https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-large-pharma-gvzk9wgh1la0ljx.html

All IMHO.

Used in the UK's NHS (other than the Manchester hospitals where it was tested) can now be ordered for use anywhere in the NHS. Fast, portable, no blood draw needed and cheap. What is there not to like?

"Genedrive® CYP2C19-ID test chosen as the preferred platform for point-of-care genotype testing prior to clopidogrel treatment for stroke patients in the NHS".

https://www.lse.co.uk/rns/GDR/nice-recommends-cyp2c19-id-kit-in-final-guidance-y8oukoeel6mfuuv.html

Can't wait until we get confirmation of other trusts placing orders.

Application for FDA approval soon no doubt.

All IMHO

When laboratory-based testing is not available." if you have not bought at least one Gendrive machine to use in this scenario? If you do not have one, then obviously you are not following the NICE recommendation? This is very important to realise. Before the recommendation as I understand it Hospitals other than the Manchester ones (who tested it for NICE) were not allowed to order the machines. NOW THEY CAN. What is going to happen?

========================

***Point-of-care testing***

1.3 Use the Genedrive CYP2C19 ID Kit point-of-care test for CYP2C19 genotype testing when laboratory-based testing is not available.

========================

GloriaMarket

Are you saying the clinicians will ignore lab testing and go straight to GDRs POC?

================================

I think once they experience the massive time advantage and convenience of the machine, and are told it's cheaper they will use it more and more. As I unserstand it the decision to go the longer lab route (which is sometimes far nmore expensive) rests with the medic. Seems obvious what they will do.

Machine, whereas before they were not even allowed to.

It's faster than a lab test by hours if not days, does not need a blood draw and is cheaper. Once they get used to using it, they will prefer to use it IMHO. If the nurses and doctors prefer to use the machine they will of course promote it for Gendrive. I can easily see it as standard in all accident and emergency and stroke victim wards. Seems obvious.

All IMHO.

Slacker246

When will lab testing not be available??????????????

==========================================

Hello,

Where does one start?

Recently none of the labs were available due to a malware attack, it was in the papers.

- Gendrive's machine would nit have been affected.

If there is a problem at the lab they deal with.

If the lab is overloaded with work.

If there is a problem getting the sample to and from the lab.

If the lab goes on strike.

Many potential reasons.

Why would NICE even make thes comments if they did not think laboratory-based testing is sometimes not available????????? Get real. The comments would NOT be there if they are not important.

***Point-of-care testing***

1.3 Use the Genedrive CYP2C19 ID Kit point-of-care test for CYP2C19 genotype testing when laboratory-based testing is not available.

1.4 Use the Genomadix Cube point-of-care test when laboratory-based testing and the Genedrive CYP2C19 ID Kit point-of-care test are not available.

Most NHS hospitals are going to order at least one machine as backup for when "laboratory-based testing is not available.".

That is more than enough to keep Gendrive busy, if not struggling to fill the orders.

All IMHO.

NICE recommends it happens to people who have had a stroke, right?

What the document says:-

1 Recommendations

1.1 Use CYP2C19 genotype testing to assess if clopidogrel is a suitable antiplatelet drug for people who have just had an ischaemic stroke or a transient ischaemic attack (TIA). CYP2C19 genotype testing is only recommended if:

quality-assurance processes and arrangements are in place for point-of-care tests

shared decision making for doing the test is established (see NICE guidance on shared decision making).

When interpreting test results, healthcare professionals should take into account that the prevalence of different CYP2C19 genotypes may vary between ethnic groups.

Laboratory-based testing

1.2 Use laboratory-based testing for CYP2C19 genotype testing.

***Point-of-care testing***

1.3 Use the Genedrive CYP2C19 ID Kit point-of-care test for CYP2C19 genotype testing when laboratory-based testing is not available.

1.4 Use the Genomadix Cube point-of-care test when laboratory-based testing and the Genedrive CYP2C19 ID Kit point-of-care test are not available.

========================================================

As I understand it previously, they did not do the test at all.

Obviously for ***Point-of-care testing*** the hospitals will need a Genedrive machine “when laboratory-based testing is not available.". This is a bit ambiguous. I should think the bigger hospitals may have their own in house lab? So maybe this comment is made for the ones that don't? In any event it clearly says, "Use the Genedrive CYP2C19 ID Kit point-of-care test for CYP2C19 genotype testing when laboratory-based testing is not available.", and you can't do that if you do not have at least one available to use, right?

Bottom line is it's faster than a lab test by hours if not days, does not need a blood draw and if cheaper. Once they get used to using it, they will prefer to use it IMHO.

https://www.nice.org.uk/guidance/dg59/chapter/1-Recommendations

All IMHO.

Also this has gone on so long now and "out of the blue" massive bills would have become apparent IMHO. Any bidder will be more confident they have a reasonable idea where PFC stand.

To see as far as possible where PFC are financially. PFC really could get a bid. To set up World wide Company takes decades and hundreds of millions of pounds. PFC are there for the taking.

All IMHO.

The road" as someone has said.

An offer to corner eventually the uk, usa and european markets?

Broker target 85.00 and we are sub 3p.

===============

Let the broker buy some first.

I have the money.

I can see it @ 14:44:29.........

5 what? shares......?

Should not at all. Psychology..................................

Able to sell @ 3.9p when we get the next RNS............... Note I have previuosly sold a shed load @ 4.6p...........

Chill...........

All IMHO.

Is .......... well I can't even find words for this situation...................... other than how long to the TR1, or how long until a sensible bid...... 7 to 10p? No worries.

Https://valueinvesting.io/GDR.L/estimates#

Maybe I should sell? That is far too low. LOL!